Uncategorized
Aerie delves into safety data for glaucoma treatment in Rocket trial
A novel once-daily glaucoma drop yielded no drug-related systemic effects or serious adverse events, results of the Rocket 2 trial showed.Aerie Pharmaceuticals hosted a webcast in March to discuss interim safety results of the phase 3 trial comparing Rhopressa (netarsudil ophthalmic solution 0.02%) with timolol 0.5%.